{"id":109277,"date":"2026-07-29T03:40:09","date_gmt":"2026-07-29T03:40:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/109277\/"},"modified":"2026-07-29T03:40:09","modified_gmt":"2026-07-29T03:40:09","slug":"british-business-headlines-gsk-investment-burberry-stake-astrazeneca-challenges-glencore-allegations-football-deal-talks","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/109277\/","title":{"rendered":"British Business Headlines: GSK Investment, Burberry Stake, AstraZeneca Challenges, Glencore Allegations, Football Deal Talks"},"content":{"rendered":"<p>In a significant economic development, pharma giant GSK announced plans to establish a global research and development headquarters in Cambridge, marking a \u00a3400 million investment under new leadership. The move represents a strategic relocation from Stevenage.<\/p>\n<p>Meanwhile, Mike Ashley&#8217;s Frasers Group continues its series of business interventions with a public disclosure of its stake in luxury retailer Burberry. This aligns with the billionaire&#8217;s history of engaging with competitor ventures.<\/p>\n<p>AstraZeneca&#8217;s executive has advocated for operating at &#8216;Chinese speed&#8217; to outpace innovative rivals, reflecting concerns of lagging like the western automotive sector. Additionally, Glencore is embroiled in legal issues, accusing a former Prax refinery owner of fraudulent actions leading to significant financial losses. English football is on the brink of a historic deal, with negotiations underway for a \u00a31.5 billion, decade-spanning agreement to prevent regulatory intervention.<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"In a significant economic development, pharma giant GSK announced plans to establish a global research and development headquarters&hellip;\n","protected":false},"author":2,"featured_media":109278,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[123],"tags":[14607,48008,53176,2031,53177,13235,132,41991,1101,250],"class_list":["post-109277","post","type-post","status-publish","format-standard","has-post-thumbnail","category-glencore","tag-astrazeneca","tag-burberry","tag-cambridge","tag-english-football","tag-frasers-group","tag-fraud","tag-glencore","tag-gsk","tag-innovation","tag-investment"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117001193031885701","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/109277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=109277"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/109277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/109278"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=109277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=109277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=109277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}